ID: ALA476343

Max Phase: Preclinical

Molecular Formula: C21H23BrN2O5

Molecular Weight: 463.33

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN1C(=O)[C@H](O)[C@H](O)[C@H]1CN[C@@H](COC(=O)c1ccc(Br)cc1)c1ccccc1

Standard InChI:  InChI=1S/C21H23BrN2O5/c1-24-17(18(25)19(26)20(24)27)11-23-16(13-5-3-2-4-6-13)12-29-21(28)14-7-9-15(22)10-8-14/h2-10,16-19,23,25-26H,11-12H2,1H3/t16-,17+,18+,19+/m0/s1

Standard InChI Key:  LKHOPRZQBRZOTI-WJFTUGDTSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 463.33

Molecular Weight (Monoisotopic): 462.0790

AlogP: 1.50

#Rotatable Bonds: 7

Polar Surface Area: 99.10

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.12

CX Basic pKa: 7.21

CX LogP: 2.06

CX LogD: 1.85

Aromatic Rings: 2

Heavy Atoms: 29

QED Weighted: 0.54

Np Likeness Score: 0.06

References

1. Fiaux H, Kuntz DA, Hoffman D, Janzer RC, Gerber-Lemaire S, Rose DR, Juillerat-Jeanneret L..  (2008)  Functionalized pyrrolidine inhibitors of human type II alpha-mannosidases as anti-cancer agents: optimizing the fit to the active site.,  16  (15): [PMID:18599296] [10.1016/j.bmc.2008.06.021]

Source

Source(1):

• Scientific Literature